Author - Jennifer Poland

Selecta Biosciences

Stifel cuts Selecta Biosciences to hold with $4 PT

Stifel downgraded Selecta Biosciences (NASDAQ:SELB) to “hold” from “buy” with a price target of $4 after the company inked a licensing deal for its SEL-212 drug candidate for the treatment of severe chronic gout with...

Stifel cuts Acorda Therapeutics PT to $1 from $2.50

Stifel reduced its price target for Acorda Therapeutics (NASDAQ:ACOR) to $1 from $2.50 and maintained its “hold” rating, citing lower than expected first quarter revenue for its Inbrija inhaled formulation of levodopa...

Interpace Biosciences Logo

AGP cuts Interpace Biosciences PT to $9.25

Alliance Global Partners lowered its price target for Interpace Biosciences (NASDAQ:IDXG) to $9.25 from a reverse split-adjusted $21, but maintained its “buy” rating, after the company posted fourth quarter...


Mackie cuts Medicure PT to $2.80 from $6.50

Mackie Research slashed its price target for Medicure (TSXV:MPH) to $2.80 from $6.50, and maintained a “hold” rating, citing highly lowered revenue estimates. The stock closed at $2.41 on April 15. Analyst Andre Uddin...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.